A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 39600 participants.
Also called NCT04505098
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 39,600 participants
- Sponsor
- Registry
-
NCT04505098
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT04505098. Randomized; single masking; primary purpose prevention. Start 2020-08-07 (actual); primary completion 2022-12-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
- Acronym
- MITIGATE
- Condition
- Covid19
- Condition
- Atherosclerosis
- Condition
- Cardiovascular Diseases
- Condition
- Upper Respiratory Tract Infections
- Intervention (Drug)
- Icosapent ethyl
- Lead sponsor
- Kaiser Permanente
- Collaborator
- Amarin Corporation
Record details
- Record id
cardio:ct-nct04505098- Content hash
22d1c9746bd1f1c781aadbd5ae3fd6c10b49952e6129a3724f9f999c1e40097c